The North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030; it is estimated to record a CAGR of 9.9% from 2022 to 2030.
Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives North America Microbiome Therapeutics Market
Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome’s role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics.
Grab PDF To Know More @ https://www.businessmarketinsights.com/sample/BMIRE00029954
North America Microbiome Therapeutics Market Overview
The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the North America microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics.
Market Segmentation
The North America microbiome therapeutics market is segmented based on type, application, end user, and country.
Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.
By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held the largest share in 2022.
By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.
Market leaders and key company profiles
- AOBiome Therapeutics Inc
- Ferring Holdings SA
- Finch Therapeutics Group Inc
- Pendulum Therapeutics Inc
- Seres Therapeutics Inc
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defence; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
